Company Overview and News

0
IFC sells shares of AU Small Finance Bank worth Rs 201 crore

2018-07-13 moneycontrol
World Bank arm International Finance Corporation (IFC) today sold 32 lakh shares of AU Small Finance Bank for Rs 201.6 crores through an open market transaction. However, the buyer of the shares could not be ascertained immediately.
GODREJPROP IFK IFX 533150

0
Godrej Properties Limited - Shareholders meeting

2018-07-09 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GODREJPROP 533150

0
Indiabulls Real Estate to sell office property in Chennai to Blackstone for ₹850crore

2018-07-06 livemint
New Delhi: Indiabulls Real Estate (IBREL) on Friday announced sale of its office project in Chennai to global investor Blackstone for Rs850 crore as part of its strategy to monetise commercial asset.
GODREJPROP 533150 532832 IBREALEST

0
Godrej Properties Limited - Allotment of ESOP/ESPS

2018-07-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GODREJPROP 533150

0
One year of GST: Fiscal deficit likely to remain under check; 3 sectors and 2 stocks to bet on

2018-06-30 moneycontrol
Year 2017 will forever be etched in Indian history as the year that saw the implementation of the biggest and most important economic reform since Independence — the Goods and Services tax (GST). It's been one year since GST came in and, given the magnitude of changes it entailed, it may be premature to pass a verdict on its success today.
GODREJPROP 533150

0
Godrej Properties to focus only on top 4 cities, exit other markets

2018-06-24 livemint
Mumbai: Godrej Properties Ltd will focus on the top four cities and exit others over a period of time, a senior executive at the Mumbai-based real estate developer said.
GODREJPROP OBZIY OBEROIRLTY 533150 533273

0
Large builders eye township projects as small firms exit

2018-06-17 livemint
Smaller and regional developers are slowly exiting the business of building townships because of funding challenges, scarcity of land and stringent regulatory norms, leaving a few large firms to rule this space.
GODREJPROP 533150

4
Deutsche Bank attributes slowdown in realty stocks to new accounting standards

2018-06-15 moneycontrol
Highlighting the fact that real estate stocks this year have been underperforming the broader markets, Deutsche Bank believes that it could be linked to uncertainties around new accounting standards.
GODREJPROP OBZIY DB OBEROIRLTY 533150 533273

Related Articles

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

WMT: Walmart Analysis and Research Report

2018-07-09 - Asif

Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...

NVRO: Nevro Corp Analysis and Research Report

2018-07-06 - Asif

Overview Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from chronic pain. Nevro has developed and commercialized the Senza® spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company's proprietary paresthesia-free HF10TM therapy, delivered by its Senza system, was demonstrated in its SENZA-RCT study to be superior to traditional SCS therapy with it being nearly twice as successful in treating back pain and 1.5 times as successful in treating leg pain when compared to traditional SCS therapy. Comparatively, traditional SCS therapy has limited efficacy in treating back pain and is used primarily for treating leg pain, limiting its market adoption. The company's SENZA-RCT study, along with its European studies, represents what the company believe is the most robust body of clinical evidence for any SCS therapy. The compa...